01—Abstract
Summary
Summary of the 10-Q filed June 7, 2011. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported strong financial performance for the quarter and six months ended April 30, 2011, with significant year-over-year increases in orders, net revenue, and net income.
Total net revenue grew 32%a and 29% for the three and six-month periods, respectively, driven by robust performance across all business segments: Life Sciences, Chemical Analysis, and Electronic Measurement. This growth was bolstered by recent acquisitions, notably Varian, Inc., which contributed significantly to revenue and order expansion. The company also successfully integrated three smaller businesses, further diversifying its portfolio.
Profitability saw a substantial improvement, with net income more than doubling in the six-month period. Cash flow from operations also demonstrated strong growth, indicating healthy operational efficiency.
Agilent continues to focus on integrating its recent acquisitions, realizing cost and revenue synergies, and investing in research and development to maintain its competitive edge in the measurement solutions market. The company appears well-positioned for continued growth, supported by strong demand in key end-markets such as pharmaceutical, biotechnology, and petrochemical sectors.
02—Key points
Key Highlights
- Total net revenue for the six months ended April 30, 2011, increased by 29% to $3.20 billion compared to $2.48 billion in the prior year, reflecting broad-based growth across segments.
- Net income for the six months ended April 30, 2011, more than doubled to $393 million, up from $187 million in the same period last year.
- Orders grew significantly across all segments, with Life Sciences up 38% and Chemical Analysis up 62% for the six-month period, indicating strong demand.
- The acquisition of Varian, Inc., completed in May 2010, continues to be a significant contributor to revenue growth, with its impact noted across multiple segments.
- Net cash provided by operating activities for the six months ended April 30, 2011, was $498 million, a substantial increase from $255 million in the prior year.
- Agilent acquired three additional businesses in the first six months of 2011 for $96 million, further expanding its capabilities and market reach.
- Electronic Measurement segment showed solid revenue growth of 21% for the six months ended April 30, 2011, driven by demand in general purpose end-markets like industrial, semiconductor, and computer sectors.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2011, Agilent Technologies, Inc. kept $0.12.
- Revenue$1.68B100.0%
- Cost of revenue−$777.0M46.3%
- Gross profit$900.0M53.7%
- Operating costs−$634.0M37.8%
- Operating income$266.0M15.9%
- Interest, other & tax−$66.0M3.9%
- Net income$200.0M11.9%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2011filed June 7, 2011Financial Statements
Q2 FY2011 against Q2 FY2010
| Line item | Q2 FY2011Q2 FY2010 | Change |
|---|---|---|
| Revenue | $1.68B$1.27B | +31.9% |
| Cost of Revenue | $777.00M$560.00M | +38.8% |
| Gross Profit | $900.00M$711.00M | +26.6% |
| R&D Expenses | $165.00M$150.00M | +10.0% |
| SG&A Expenses | $469.00M$407.00M | +15.2% |
| Operating Expenses | $1.41B$1.12B | +26.3% |
| Operating Income | $266.00M$154.00M | +72.7% |
| Interest Expense | $20.00M$22.00M | −9.1% |
| Net Income | $200.00M$108.00M | +85.2% |
| EPS (Basic) | $0.58$0.31 | +87.1% |
| EPS (Diluted) | $0.56$0.31 | +80.6% |
| Shares Outstanding (Basic) | 347.00M348.00M | −0.3% |
| Shares Outstanding (Diluted) | 355.00M354.00M | +0.3% |
05—Questions
Frequently Asked Questions
How did the acquisition of Varian, Inc. impact Agilent's financial performance in this period?
The acquisition of Varian, Inc., completed in May 2010, had a significant positive impact on Agilent's financial performance. Varian's results are included in Agilent's consolidated statements, contributing substantially to the reported increases in orders and net revenue across all business segments, particularly Life Sciences and Chemical Analysis. The company expects to realize significant cost and revenue synergies from this integration.
What is the outlook for Agilent's different business segments?
The outlook appears positive across the board. Life Sciences and Chemical Analysis are experiencing strong order and revenue growth, driven by demand in pharmaceutical, biotechnology, and petrochemical markets, further enhanced by recent acquisitions. The Electronic Measurement segment also showed solid growth, benefiting from improved demand in industrial, semiconductor, and computer markets, with expectations for continued strength in wireless manufacturing and digital test businesses.
What is the company's cash flow situation and how is it being utilized?
Agilent demonstrated strong operating cash flow generation, with $498 million provided by operating activities in the first six months of 2011, nearly double the previous year. The company utilized a significant portion of cash in financing activities, primarily for debt settlement and share repurchases. Agilent maintained a healthy cash balance of $2.98 billion as of April 30, 2011, with no borrowings outstanding under its credit facility.
Are there any significant risks or challenges that investors should be aware of?
The company faces risks related to depressed general economic conditions, which could reduce demand for its products. Dependence on contract manufacturing, the need for timely new product introductions, and potential intellectual property disputes are also noted risks. Furthermore, the successful integration of acquisitions, particularly Varian, remains critical to realizing expected synergies and avoiding potential integration challenges.
06—Continue